Changchun High-tech: Subsidiary GenSci161 Injectable Clinical Trial Application Accepted

Changchun High-tech announced that its holding subsidiary, Jinsai Pharmaceutical, has received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci161 injection. GenSci161 injection is a type 1 biopharmaceutical developed independently by Jinsai Pharmaceutical, intended for the treatment of non-infectious uveitis. Non-infectious uveitis is a heterogeneous inflammatory disease affecting the uvea and surrounding tissues, with a global annual incidence rate of 17/100,000 to 52/100,000 and an annual prevalence rate of 115/100,000 to 204/100,000. Currently, the only approved biologics for this indication are anti-TNF drugs, but GenSci161 injection is expected to provide a new treatment option.